Do Peptides Work? Evidence, Studies and the 2026 Policy Guide

If you searched whether peptides work, the short answer is that it depends on the exact peptide, how it is given, who was studied and what was measured. According to the Associated Press report on the policy, most of the data on peptides comes from animal studies. On October 30, 2026, HHS published an interim enforcement discretion policy covering six named peptides in specific forms and routes, which lets qualifying compounding pharmacies make them under conditions. This page explains what those six peptides have in human research, how to match a study to the product in front of you, and what to check before you decide.

What is a peptide, and what does the new policy cover?

Peptides are short chains of amino acids, smaller than a protein. ABC News explains that some, such as insulin and GLP-1 medicines, are FDA-approved drugs, while others have spread online with little robust data behind them (ABC News report on the advisory vote). The peptides in this policy are the ones that pharmacies have wanted to compound.

Compounding means a pharmacy or physician prepares a drug for one identified patient on a valid prescription. The federal rules are in the 21 U.S.C. 353a compounding statute, which also requires that bulk ingredients meet a listed standard. The six peptides are not on the 503A bulks list, and HHS’s policy works alongside that list rather than changing it.

Which six peptides does the policy name?

The Federal Register enforcement discretion notice names six peptides. LegitScript’s summary of the policy lists each as covered only in the form and routes below.

Oral forms have one extra requirement: documentation that the specific formulation achieves adequate oral bioavailability in humans. The policy requires a single active pharmaceutical ingredient; LegitScript reads this as excluding combinations with any other active ingredient, such as BPC-157 with TB-500.

Is it legal to get these peptides now?

Not in the usual sense. HHS says it does not intend to take enforcement action against a qualifying 503A pharmacy or licensed physician compounding one of the six peptides, when the listed conditions are met. The six are not on the 503A bulks list, and HHS may revise or withdraw the policy. Enforcement discretion is not FDA approval.

LegitScript’s summary of the policy lists ten conditions. The main ones are:

• The peptide, form and route match the covered list above.
• Sourcing is from FDA-registered manufacturers, with a valid certificate of analysis (COA) from a facility registered under section 510.
• The original manufacturer is FDA-registered, follows current good manufacturing practice, and its physical location appears on the COA.
• Compounded products, serious adverse events and quality problems are reported to FDA and the relevant states.
• The label reads “This is a compounded drug product. Not for resale.”
• The product contains a single active pharmaceutical ingredient.
• Oral forms carry the bioavailability documentation described above.
• Any delivery device packaged with the drug is an FDA 510(k)-cleared syringe.
• A patient-specific prescription is in place, and the work is done without insanitary conditions.

The policy applies to qualifying 503A pharmacies and physician compounders. It does not cover 503B outsourcing facilities, and according to the BakerHostetler policy summary, it does not apply to products sold as research chemicals or dietary supplements.

How did the policy get here?

Who may fit this route, and who should pause?

This is a decision for you and a licensed prescriber. The table shows where a closer look makes sense and where to pause or ask first.

What do the human studies show for each peptide?

BPC-157: the three main reports

The human reports this page found are mostly for BPC-157, and they differ sharply by route, condition and group of people. They should not be merged into one answer about BPC-157.

• 2024 bladder report. The 2024 BPC-157 bladder pilot study gave 12 women aged 39 to 76 with interstitial cystitis injections of BPC-157 around the inflamed bladder area during one procedure. None had responded to pentosan polysulfate. On the Global Response Assessment, 10 of 12 women rated their success at 100% and 2 rated it at 80%. No adverse events were reported. This was a single-group report with no comparison arm.
• 2025 intravenous pilot. The 2025 intravenous BPC-157 pilot study gave two adults who had previously received intravenous BPC-157 infusions on two consecutive days at a private clinic in Florida. Blood tests and vital signs showed no measurable effects on the heart, liver, kidney, thyroid or blood glucose markers, and no side effects were reported. The authors say future studies are needed to confirm safety.
• FDA’s advisory review. FDA reviewers wrote that there was a lack of evidence to reach a conclusion on BPC-157’s effectiveness in ulcerative colitis, as reported by The Hill’s coverage of the FDA briefing.

The other five peptides

The human studies covered on this page are about BPC-157 and oral collagen peptides. For the other five, the record is FDA’s safety-risk list and the advisory vote.

The FDA list of bulk drug substances with safety risks, content current as of April 22, 2026, the date the six left Category 2, reports the following. FDA said it had identified no human exposure data for KPV, MOTS-c and TB-500. For BPC-157, epitalon and semax it reported limited or no safety information for the proposed routes. For BPC-157, epitalon, semax, TB-500 and MOTS-c it named possible immune-reaction risk from aggregation or peptide-related impurities. These are FDA’s risk entries, not study results.

Oral collagen peptides: a different product

Oral collagen peptide products are a separate category and are not among the six. The 2023 oral collagen peptide trial was randomized, double-blinded and placebo-controlled. It enrolled 100 women aged 30 to 60 who took 1,650 mg per day of a collagen peptide preparation or placebo for 12 weeks. Compared with placebo, skin desquamation and hydration improved by week 4, and skin wrinkling and elasticity improved by week 12. No side effects were reported in the safety test. Several authors list affiliations with the companies that make the preparation. The finding belongs to that preparation, that dose and those 100 women.

Topical cosmetic peptides

A 2017 topical peptide cosmeceutical review describes peptides used in skin products to signal skin repair and modulate pigment and inflammation. The review says clinical efficacy evidence is often weak, absorption can be poor, and prices can be high. It reviews the category rather than testing any single serum.

What is established, what is claimed, and what is still open?

Established facts

• HHS’s policy covers six named peptides in listed forms and routes, under enforcement discretion, with ten conditions.
• Each of the six was in FDA’s Category 2 from September 2023 to April 22, 2026.
• The federal statute allows compounding for an identified patient on a valid prescription.

Statements from the certifier and advocacy groups

• LegitScript says the policy does not mean these peptides are FDA-approved, and that certification does not guarantee access to advertising or payment services. These are its own statements as a certification organization. (LegitScript policy update, November 2026)
• The Partnership for Safe Medicines, an advocacy group, filed a citizen petition on October 16, 2026, asking FDA not to allow compounding of the six peptides, which it calls untested and poorly defined (Partnership for Safe Medicines petition).
• Ars Technica reports that sellers have claimed, without evidence, that these drugs can improve appearance, boost energy and help heal injuries (Ars Technica report on unproven peptides).

Our reading

Read together, the human reporting for BPC-157 is a set of small, single-condition reports, and for most of the six the public record is regulatory rather than clinical. The new policy changes who may compound these peptides and under what conditions. It does not change what the human research shows about them.

Where the reports disagree, and what remains open

• The Partnership for Safe Medicines petition lists emideltide and semax as the six peptides. ABC News reports that the advisory panel rejected emideltide and recommended epitalon. The HHS policy names epitalon, so follow that list.
• LegitScript dates HHS’s filing to October 28, while the Federal Register publication date is October 30.
• Open items include the comment period, which closes November 13, 2026, the separate rulemaking on the 503A list, and how pharmacies will apply the ten conditions in practice. Check the Federal Register notice for any revision after November 13.

What does it cost, and what is the total commitment?

Pricing for these peptides is set by each pharmacy, clinic or telehealth service. Prices and bundles change, so check today’s price directly with the company before you agree to anything. Large telehealth companies have said they plan to offer peptides if federal access eases, according to the Associated Press report on the policy.

Ask for these in writing before you pay:

• The total cost of the peptide for the supply you are offered
• Any prescriber visit fee and shipping charge
• Whether recurring charges apply
• The refund and cancellation terms
• Who handles adverse event reports for the product

What are the safety risks and side effects?

The human reports above describe side effects as they were recorded in each study.

HHS’s policy states that compounded drugs may pose risks to patients, and that FDA does not review their safety, effectiveness or quality before they are marketed. A 2023 review in the 2023 compounding legal and clinical review noted that, apart from 503B facilities, compounding pharmacies were not required to report adverse events to FDA. The new policy adds reporting of serious adverse events for covered products.

The Partnership for Safe Medicines reported that it bought five vials of unapproved peptides from telehealth services in the past 45 days. The products came from pharmacies licensed in Texas and Pennsylvania, and none of those businesses held a license to dispense injectables in California. The group also reported that a vial bought at a New York City bodega, which CBS News sent for testing, contained no retatrutide and showed bacterial colonies, according to Partnership for Safe Medicines petition.

Is the seller legitimate? Checks to run before you pay

Certification is a separate step from checking the pharmacy and the prescription. Use these checks on both.

• Facility type. FDA’s FDA compounding inspections and actions list shows facilities with FDA inspection or enforcement history, so it can show whether a named pharmacy has FDA actions on record. It is not a register of every 503A or 503B pharmacy. Confirm licensure and facility type with the state board of pharmacy and by asking the pharmacy directly.
• State license. The state board of pharmacy license should match the business name and cover the state where you receive the product.
• Prescription. The prescription should be patient-specific and come from a licensed prescriber who knows your history.
• Labels and paperwork. Ask for the COA, the original manufacturer and its location, and confirm the label reads “This is a compounded drug product. Not for resale.” Confirm any syringe is FDA 510(k)-cleared.
• Warning phrases. LegitScript lists these as signals that promotion has crossed a line: efficacy or safety claims compared with FDA-approved drugs; dosing recommendations for an unapproved drug; claims that a peptide repairs or heals a specific condition; calling a substance scientifically backed without disclosing that most research has not been done in humans; and implying FDA approval (LegitScript promotion warning signs).
• Research-use-only and overseas sellers. ABC News reports that many people buy these compounds from overseas sellers as unregulated “research chemicals,” with no doctor involved and no guarantee of what is in the vial. The policy does not cover products sold that way.
• Name and identity. Check that the seller’s name on the website, the license and the prescription label match one another.
• Renewal and refunds. Get the renewal and refund terms in writing from the pharmacy or clinic before any payment.

What are the alternatives, including FDA-approved options and doing nothing?

• FDA-approved medicines. Insulin and GLP-1 medicines are FDA-approved drugs, as ABC News notes. For emideltide, which the panel rejected, the agency noted that approved treatments already exist for the conditions it was proposed for. A prescriber can tell you whether an approved option fits your goal.
• Doing nothing. Waiting is a real choice. The comment period runs to November 13, 2026, and HHS may revise the policy.
• Study-based comparison. If a peptide is on your list, compare its exact study with the product you would buy, using the clinical study design guide and the study populations dosing and outcomes guide.
• Other product categories. For skin goals, oral collagen peptide trials and topical cosmetic peptide reviews are different categories, so compare each one on its own study. See the peptide before and after results evidence page for how claims are framed.

How do you verify a peptide before you pay?

1. Write down the exact peptide, form and route, not only the brand name.
2. Confirm it is one of the six, in the covered form and route.
3. Confirm the pharmacy holds a license from its state board of pharmacy that covers where you live, check its FDA inspection history on FDA’s compounding list, and ask whether it is a 503A facility.
4. Ask for a patient-specific prescription from a licensed prescriber.
5. Ask for the COA, the original manufacturer and its location, and any oral bioavailability documentation.
6. Get the total cost, fees, shipping, recurring charges and refund terms in writing.
7. Read the study for the same molecule, route, population and outcome, using the ingredient evidence vs marketing claims guide and the meta-analyses and systematic reviews guide.
8. Save the prescription, COA, label, invoices and written correspondence.
9. Ask the pharmacy how serious adverse events are reported to FDA and to your state.

Frequently asked questions

Are compounded peptides regulated by the FDA?

Partly. A 2023 dermatology review describes a split in which state boards of pharmacy oversee day-to-day 503A pharmacy work. That review and the University of Maryland compounding overview both say 503B outsourcing facilities must follow current good manufacturing practice and are regulated by FDA.

Can a doctor prescribe one of these peptides?

Under the statute, a compounded drug is made for an identified patient on a valid prescription from a licensed practitioner. The policy also covers licensed physician compounders. Whether a particular prescriber will prescribe one of these peptides is a question for that prescriber.

Is GHK-Cu FDA-approved for human use?

GHK-Cu is not one of the six peptides in HHS’s policy. FDA’s risk page lists injectable GHK-Cu and says there are limited human data on its safety. To check approval status for a specific product, search FDA’s Drugs@FDA database or ask a pharmacist.

How do you check whether a pharmacy compounds these peptides?

Check the pharmacy’s state license and facility type with the state board of pharmacy and by asking the pharmacy, then look up its FDA inspection and enforcement history on FDA’s compounding list. Ask whether it will compound the six peptides in the covered form and route, and ask for its COA and original manufacturer before you proceed.

The short answer

Peptides work, as a research question, only for the exact molecule, form, route, group of people and outcome a study measured. For six peptides, HHS now allows a narrow compounding path under its enforcement discretion policy. Before any order, match the study to the product, check the pharmacy, and get the cost and refund terms in writing. Check the Federal Register notice again after November 13, 2026.

By ClinicalStudyConnect.com Research Desk

This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.